Shots:
- Memo Therapeutics has reported P-II (SAFE KIDNEY II) trial data assessing potravitug vs PBO for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients (n=95)
- Trial didn’t meet its 1EP of undetectable BKPyV DNAemia but showed superior viral response (≥1-log₁₀ reduction) & resolution of biopsy-proven BKPyVAN by Wk. 20, with histological improvement from 51.2% to 31.6% vs 23.8% to 24.4%, with 61% pts on 1000mg vs 40.5% achieving ≥1-log₁₀ reduction or levels below LLOQ; further data to be presented at World Transplant Congress
- Memo plans to advance potravitug to P-III trial based on P-II (SAFE KIDNEY II) trial results & engage with regulatory authorities to discuss trial design by late 2025
Ref: GlobeNewsWire | Image: Memo Therapeutics | Press Release
Related News:- Apnimed Reports Topline P-III (LunAIRo) Trial Data of AD109 for Obstructive Sleep Apnea (OSA)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
